Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Status:
RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP)

Phase:

PHASE2

Details

Lead Sponsor:

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Collaborator:

Biomedical Advanced Research and Development Authority

Treatments:

Anti-Bacterial Agents
meropenem and vaborbactam